BAM15

BAM15 is a small-molecule mitochondrial protonophore, not a peptide, belonging to the furazano[3,4-b]pyrazine (oxadiazolopyrazine) chemical class. Its formal chemical name is 5-N,6-N-bis(2-fluorophenyl)-[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine (molecular formula C16H10F2N6O; molecular weight approximately 340.3 g/mol; CAS 210302-17-3). Researchers distinguish it clearly from peptide actives such as GHK-Cu or BPC-157: BAM15 is a synthetic organic compound acting directly on mitochondrial membrane biophysics rather than through receptor-mediated signalling in the classical sense.

BAM15 was first identified by Kenwood and colleagues at the University of Virginia in a 2014 phenotypic screening study published in Molecular Metabolism. The team screened a library of over 5,000 compounds in rat L6 myoblasts for the ability to increase cellular oxygen consumption, followed by counter-screens to eliminate reactive-oxygen-species-generating hits and dose-response validation using extracellular flux (Seahorse) analysis. BAM15 emerged as a genuine mitochondrial protonophore, chemically unrelated to earlier uncouplers such as FCCP (carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone) or the industrial/diet-drug compound 2,4-dinitrophenol (DNP), but with a critical pharmacological distinction: unlike FCCP and DNP, BAM15 uncouples mitochondrial respiration without depolarizing the plasma membrane, a property confirmed by whole-cell electrophysiology in the original discovery paper.

This selectivity is the reason BAM15 attracted sustained research interest. Classical uncouplers such as DNP produce dangerous, poorly controllable increases in whole-body heat production and have a narrow (and historically lethal) therapeutic window. Because BAM15 appeared to uncouple mitochondria over a wide dose range with comparatively little cytotoxicity in cultured cells, it became a tool compound for probing whether mild, “titratable” mitochondrial uncoupling could be exploited to increase energy expenditure and improve metabolic parameters in models of obesity, insulin resistance, and, more recently, in cancer cell and skeletal muscle research, without the acute safety liabilities of older uncoupling agents.

1. Mitochondrial Proton Shuttling (Uncoupling)

BAM15 acts as a protonophore, shuttling protons across the inner mitochondrial membrane independently of the adenine nucleotide translocase (ANT). This collapses the proton-motive force that normally drives ATP synthase, uncoupling substrate oxidation from ATP production. Cells respond by increasing oxygen consumption and substrate (glucose and fatty acid) oxidation to maintain ATP supply, with the “excess” energy released as heat rather than being conserved as ATP. In vitro potency assays reported BAM15 as roughly sevenfold more potent than DNP at increasing oxygen consumption (EC50 approximately 1.4 uM versus approximately 10.1 uM for DNP).

2. Selective Sparing of the Plasma Membrane

A defining feature of BAM15, established in the original discovery work, is that it does not depolarize the plasma membrane at concentrations that robustly uncouple mitochondria. The precise biophysical basis for this selectivity (proposed to relate to differential proton-donating capacity or membrane lipid environment) has not been fully resolved and remains an active question in the literature.

3. AMPK Activation

Downstream of the fall in cellular ATP/AMP ratio produced by mild uncoupling, BAM15 robustly activates AMP-activated protein kinase (AMPK). In vascular smooth muscle cells, BAM15 activated AMPK far more potently than reference activators such as metformin or AICAR. AMPK activation is mechanistically linked to increased fatty acid oxidation, suppression of lipogenic gene expression (including Srebf1, Fasn, and Scd1 in adipose tissue), and stimulation of mitochondrial biogenesis pathways in the animal studies described below.

Cell Studies

In rat L6 myoblasts and other cultured cell lines, BAM15 dose-dependently increased oxygen consumption rate without the marked cytotoxicity seen with equivalent uncoupling doses of FCCP or DNP. In C2C12 myotubes, BAM15 did not reduce cell viability at concentrations up to 100 uM and produced less caspase-3/7 activation (a marker of apoptosis) than comparator uncouplers. In cultured vascular smooth muscle cells, BAM15 potently activated AMPK and relaxed phenylephrine-constricted rat mesenteric arteries ex vivo. Separately, BAM15 has been investigated in cancer cell models: it suppressed proliferation of triple-negative breast cancer cells (MDA-MB-231 and murine EO771 lines) in vitro and reduced tumour growth in corresponding mouse models, and has also been reported to inhibit proliferation of acute myeloid leukaemia cells via reactive-oxygen-species induction, although the specific concentration-response data for this study were not independently verifiable from the available literature. These oncology findings remain preliminary and mechanistically distinct from the metabolic-disease research programme.

Animal Studies

The two principal in vivo studies were published independently in 2020 by overlapping academic groups.

Alexopoulos et al. (Nature Communications, 2020) administered BAM15 to male C57BL/6J mice fed a Western-style diet (45% fat, 16% sucrose), using both acute oral gavage (10 to 200 mg/kg) and chronic dietary admixture (0.05 to 0.15% w/w) protocols. In an 8-day prevention study, dietary BAM15 at 0.10 to 0.15% w/w completely prevented diet-induced fat mass gain without affecting lean mass or food intake. In a 9-week reversal study (4 weeks of diet-induced obesity followed by 5 weeks of 0.1% w/w BAM15), treated mice weighed approximately 15% less than untreated controls, driven specifically by fat loss; glucose intolerance and hyperinsulinemia were reversed within three weeks, and hyperinsulinemic-euglycemic clamp studies confirmed normalized whole-body insulin sensitivity by six weeks. Liver triglyceride content was restored to chow-fed levels and plasma triglycerides fell by approximately 29%. Energy expenditure, measured by indirect calorimetry, increased roughly 15% during the dark cycle with chronic dosing.

Axelrod et al. (EMBO Molecular Medicine, 2020) independently confirmed these findings in diet-induced obese C57BL/6J mice fed a 60% high-fat diet, using 0.1% w/w dietary BAM15 (approximately 85 mg/kg/day). By day 20, treated mice weighed roughly 7.5 g less than controls, with reduced fat mass and preserved lean mass; food intake was unaffected until later in the study. Fasting glucose and insulin were both significantly reduced, and hepatic lipid accumulation was reduced by approximately 75% relative to untreated controls. Notably, BAM15-treated mice showed better glycaemic control than calorie-restriction-matched controls of similar body weight, while better preserving lean mass, suggesting effects beyond simple caloric deficit.

Additional rodent work has examined BAM15 in other contexts: a single intraperitoneal dose (1 to 5 mg/kg) protected mice against renal ischemia-reperfusion injury in the original discovery paper, and a 2025 preprint (not yet peer-reviewed) reported that dietary BAM15 preserved contractile force and mitochondrial respiration in the skeletal muscle of aged mice, a model of sarcopenia, with a more pronounced effect in males than females. As this work is unpublished and non-peer-reviewed, it should be regarded as preliminary.

Human Clinical and Cosmetic Studies

No human clinical trials of BAM15 have been published, and no study is registered on ClinicalTrials.gov. Every source in the current literature, including a 2023 narrative review in Frontiers in Endocrinology, explicitly frames BAM15 as a preclinical research compound. There are no human pharmacokinetic, safety, efficacy, or cosmetic data of any kind available for BAM15 at this time.

Safety data for BAM15 are confined to rodent studies and should not be extrapolated to humans. In the chronic dietary dosing studies described above, mice tolerated BAM15 at doses up to 200 mg/kg (acute) or sustained dietary exposure at 0.1 to 0.15% w/w without changes in body temperature, and with normal liver enzymes (ALT, AST, GLDH), normal creatine kinase, and normal creatinine; blood urea nitrogen was mildly elevated (approximately 22%) but remained within the normal reference range. Full histopathological examination in the EMBO Molecular Medicine study found no adverse pathology in liver, kidney, muscle, heart, or brain, and no evidence of ketosis. By comparison, the classical uncoupler DNP has a no-observed-adverse-effect level of only around 25 mg/kg in similar rodent studies, whereas BAM15 was tolerated up to 200 mg/kg in the cited work, a favourable margin that is frequently cited as BAM15’s key advantage over older uncoupling agents.

No human toxicology, dose-escalation, or adverse-event data exist. There is no established human-equivalent dose, no data on long-term organ safety, immunogenicity, or drug interactions, and no regulatory safety review has been conducted for BAM15 in humans. Given its mechanism as a mitochondrial uncoupler, a pharmacological class with a documented history of serious harm in humans when older agents (notably DNP) were misused outside of supervised research settings, any research use warrants strict adherence to laboratory protocols and animal-model dosing frameworks only.

Pharmacokinetic characterization in mice found BAM15 to have oral bioavailability of approximately 67%, a plasma half-life of about 1.7 hours, and a peak plasma concentration (Cmax) of roughly 8.2 uM following oral gavage. The compound has low aqueous solubility and is typically formulated in a methylcellulose vehicle for oral dosing in rodent studies; it distributes primarily to the liver and is largely cleared within approximately four hours of a single dose. Sustained dietary admixture (0.1% w/w) maintains steady-state plasma concentrations in the 5 to 10 uM range throughout the feeding period. No formal absorption-distribution-metabolism-excretion (ADME) study or cytochrome P450 interaction profile has been published for BAM15; this remains a genuine gap in the available data rather than an established finding.

BAM15 is a mechanistically well-characterized mitochondrial uncoupler with a growing and internally consistent rodent literature showing reduced fat mass, improved insulin sensitivity, and reduced hepatic lipid accumulation, achieved without the loss of lean mass, hyperthermia, or marked toxicity that limited earlier uncoupling agents such as DNP. Its principal mechanistic novelty, uncoupling mitochondrial respiration while sparing the plasma membrane, is well documented in vitro but not yet fully explained. The animal data, drawn from at least two independent laboratories using overlapping but distinct high-fat-diet models, are reasonably concordant on core findings (fat-specific weight loss, improved glycaemic control, preserved lean mass). However, this evidence base rests entirely on rodent models; there is no human data of any kind, no pharmacokinetics, no safety data, no efficacy data, and BAM15 has no regulatory approval or clinical development pathway. Emerging cell and animal work in oncology and skeletal muscle biology broadens BAM15’s research relevance beyond metabolic disease, but this work is preliminary, and in the case of at least one skeletal-muscle study, not yet peer-reviewed. BAM15 remains strictly a research-use compound.

Kenwood et al. 2014, Molecular Metabolism (original discovery paper).

Alexopoulos et al. 2020, Nature Communications (open access).

Axelrod et al. 2020, EMBO Molecular Medicine (open access).

Xiong et al. 2023, Frontiers in Endocrinology review.

1. Kenwood BM, Weaver JL, Bajwa A, Poon IK, Byrne FL, Murrow BA, et al. Identification of a novel mitochondrial uncoupler that does not depolarize the plasma membrane. Mol Metab. 2014;3(2):114-123. doi: 10.1016/j.molmet.2013.11.005.

2. Alexopoulos SJ, Chen SY, Brandon AE, Salamoun JM, Byrne FL, Garcia CJ, et al. Mitochondrial uncoupler BAM15 reverses diet-induced obesity and insulin resistance in mice. Nat Commun. 2020;11:2397. doi: 10.1038/s41467-020-16298-2.

3. Axelrod CL, King WT, Davuluri G, Noland RC, Hall J, Hull M, et al. BAM15-mediated mitochondrial uncoupling protects against obesity and improves glycemic control. EMBO Mol Med. 2020;12(7):e12088. doi: 10.15252/emmm.202012088.

4. Xiong G, Zhang K, Ma Y, Song Y, Zhang W, Qi T, et al. BAM15 as a mitochondrial uncoupler: a promising therapeutic agent for diverse diseases. Front Endocrinol (Lausanne). 2023;14:1252141. doi: 10.3389/fendo.2023.1252141.

5. Zunica ERM, Axelrod CL, Cho E, Spielmann G, Davuluri G, Alexopoulos SJ, et al. Breast cancer growth and proliferation is suppressed by the mitochondrial targeted furazano[3,4-b]pyrazine BAM15. Cancer Metab. 2021;9:36. doi: 10.1186/s40170-021-00274-5.

6. Tai Y, Li L, Peng X, Zhu J, Mao X, Qin N, et al. Mitochondrial uncoupler BAM15 inhibits artery constriction and potently activates AMPK in vascular smooth muscle cells. Acta Pharm Sin B. 2018;8(6):909-918. doi: 10.1016/j.apsb.2018.07.010.

7. Gao ZX, Cui ZL, Zhou MR, Fu Y, Liu F, Zhang L, et al. The new mitochondrial uncoupler BAM15 induces ROS production for treatment of acute myeloid leukemia. Biochem Pharmacol. 2022;198:114948.

8. Mitochondrial uncoupler BAM15 improves skeletal muscle function and mitochondrial respiration in sarcopenia [preprint, not peer-reviewed]. bioRxiv. Posted 2025 Oct 30. doi: 10.1101/2025.10.30.685477.